Phase I, first-in-human clinical trial to evaluate safety of infusion of STAb-T19 cells: genetically modified T lymphocytes secreting αCD19xαCD3 bispecific antibodies for malignant B-cell neoplasms
Фаза 1 – тестване на безопасността при малка група хора
Заболявания:
Malignant B-cell neoplasms
Спонсор: Fundacion Para La Investigacion Biomédica Del Hospital Universitario 12 De Octubre
Налично на:
БГ
Обобщение
Trial status: Authorised
Кой може да участва
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 24 participants
БГ
EN